Literature DB >> 28242483

Classical rather than genetic risk factors account for high cardiovascular disease prevalence in Lithuania: A cross-sectional population study.

Neringa Burokienė1, Ingrida Domarkienė2, Laima Ambrozaitytė2, Ingrida Uktverytė2, Raimonda Meškienė2, Dovilė Karčiauskaitė3, Vytautas Kasiulevičius4, Virginijus Šapoka4, Vaidutis Kučinskas2, Zita Aušrelė Kučinskienė3.   

Abstract

PURPOSE: Cardiovascular disease (CVD) mortality accounts for 54% of all deaths in Lithuania, making it the highest among all of the European Union countries. We evaluated the prevalence of several CVD risk factors, including lifestyle, blood biochemistry and genetic predisposition to determine the reasons behind significantly increased CVD prevalence in Lithuania.
MATERIALS AND METHODS: In total 435 volunteers of Lithuanian ethnicity and stable geographic settlement for 3 generations, had their anthropometric, biochemical and behavioural risk factors measured. A randomly selected sample of 166 volunteers had their 60 CVD risk alleles genotyped. The prevalence of risk alleles and cumulative CVD genetic risk score were compared with population of North-West European origin (CEU) using data from the phase 3 HapMap project.
RESULTS: CVD was present in 33.8% of study volunteers, 84% of participants consumed alcohol, 21% were current smokers and only 30% of participants engaged in higher levels of physical activity. Also, the average BMI (males 28.3±4.3kg/m2, females 27.3±5.0kg/m2), total cholesterol (males 6.1±1.2mmol/L, females 6.2±1.0mmol/L) and LDL-cholesterol (males 4.1±1.1mmol/L, females 4.1±1.0mmol/L) were above the normal values. The cumulative genetic susceptibility to develop CVD in Lithuanians was only 1.4% higher than in CEU population.
CONCLUSIONS: High BMI and poor population plasma lipid profile are the major contributing factors to high CVD mortality and morbidity in Lithuania. Smoking, alcohol consumption and preliminary genetic predisposition results do not explain the difference in CVD mortality between the Lithuanian and wider European populations. CVD prevention programmes in Lithuania should primarily focus on weight loss and improving blood lipid control.
Copyright © 2017 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Dyslipidemia; Genotypes; Lifestyle risk reduction; Lithuania

Mesh:

Substances:

Year:  2017        PMID: 28242483     DOI: 10.1016/j.advms.2016.08.005

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  4 in total

1.  Applying the CHA2DS2-VASc score to predict the risk of future acute coronary syndrome in patients receiving catheter ablation for atrial fibrillation.

Authors:  Ching-Yao Chou; Yun-Yu Chen; Yenn-Jiang Lin; Kuo-Liong Chien; Shih-Lin Chang; Ta-Chuan Tuan; Li-Wei Lo; Tze-Fan Chao; Yu-Feng Hu; Fa-Po Chung; Jo-Nan Liao; Chin-Yu Lin; Ting-Yung Chang; Shih-Ann Chen
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-28

2.  Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta-analysis.

Authors:  Pradyumna Agasthi; Justin Z Lee; Sai Harika Pujari; Andrew S Tseng; Justin Shipman; Diana Almader-Douglas; Hasan Ashraf; Farouk Mookadam; Floyd David Fortuin; Nirat Beohar; Reza Arsanjani; Siva Mulpuru
Journal:  J Arrhythm       Date:  2020-01-08

3.  The effect of apolipoprotein E gene polymorphism and Lp(a) levels on coronary artery disease with atrial fibrillation.

Authors:  Yong Li; Lei Chen; Yameng Shao; Min Zhang; Li Zhi; Yuan Lu
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

4.  Polygenic risk for coronary artery disease in the Scottish and English population.

Authors:  Chuhua Yang; Fabian Starnecker; Shichao Pang; Zhifen Chen; Ulrich Güldener; Ling Li; Matthias Heinig; Heribert Schunkert
Journal:  BMC Cardiovasc Disord       Date:  2021-12-07       Impact factor: 2.174

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.